ImmuneRegen and BioCure join hands to develop wound-healing product

Under the recently executed material transfer agreement, BioCure will utilize ImmuneRegen’s Homspera for the development of a combination product composed of the potential wound-healing therapeutic Homspera and BioCure’s GelSpray, a spray-on liquid bandage that has obtained 510(k) market clearance from the FDA.

The combination of Homspera with BioCure’s wound dressing may provide a sterile wound healing product in an easily applied spray-on configuration. BioCure’s hydrogel technology is said to allow the liquid bandage to be applied painlessly to hard-to-cover areas such as between fingers and toes or over joints.

Hal Siegel, ImmuneRegen’s vice president and chief scientific officer, said: “In addition, we have shown Homspera can stimulate blood-forming stem cells to produce white blood cell precursors, particularly, granulocytes and macrophages, which play a role in wound repair. This combination of enhanced fibroblast growth and increased immune system cells suggest a role for Homspera in improving wound and lesion healing.”